One of nature’s first choice strains
The probiotic strain chosen by nature for humans - originated from breast milk
Sourced originally from the breast milk of a native Andes woman, it has been discovered that this probiotic species has co-evolved with humans since before the continents started to drift apart 100 million years ago. DNA analysis research also shows that L. reuteri remains faithful to its host through evolution; however, due to our ‘modern’ lifestyle, its abundance has been threatened.

Since 1990, 148 human clinical trials in 14,504 individuals of all ages, combined with numerous experimental studies, have revealed the safety and health benefits of this probiotic across various conditions, with more research still to come.

Lactobacillus reuteri DSM 17938 is one of the most clinically tested probiotics on the market today for gastrointestinal health.
L. reuteri is one of the most well researched probiotic species.
DSM 17938 is a powerful strain of L.reuteri
Over 140 clinical trials in more than 14,000 people of all ages, shows this human evolved strain is clinically effective, even at low doses. 
Studies in infants through to the older population have shown superior efficacy in a wide variety of health conditions and for everyday gut health.

All 148 clinical trials to date have been tested on this single strain alone, providing clear assurances of its health benefits.

For a complete list of these trials and doses, please contact your healthcare professional who can obtain a copy of the L. reuteri DSM 17938 clinical guide from
Origin and evolution of L.reuteri DSM 17938
Lactobacillus reuteri

  • Has evolved to co-exist with humans

  • Exhibits well developed mutualistic interactions and favourable effects (clinical research shows interactions with the host in a positive manner)

  • Has lost abundance in modern societies

This mutualistic probiotic should be present in human gastrointestinal tracts today.

Watch 2 min video on the origin and evolution of the symbiotic bacteria L. reuteri

​​​​​​​L. reuteri is frequently found in tribes with a ‘natural lifestyle’ but is now rare in people with a ‘modern lifestyle’.
Clinical research on DSM 17938 has shown benefits
in the following areas:
  • Constipation
  • Functional abdominal pain
  • IBS
  • Gastroenteritis
  • Infection protection
  • Immune modulation
  • Pathogenic overgrowth
  • SIBO
  • Helicobacter pylori
  • Antibiotic-associated side effects
  • Microbiota modulation
  • GI health
  • Allergy prevention and treatment
  • Metabolic disorders
  • IBD
  • Cystic fibrosis
  • Lactose intolerance
  • Regurgitation
  • Colic prevention and treatment
  • Cancer treatment-related diarrhoea
From common conditions, such as reflux, constipation and diarrhoea to more complex issues, such as small and large intestinal bacterial overgrowth and the invasive Helicobacter pylori, this probiotic strain has been tested and shown to be helpful in numerous conditions.

Research also shows L. reuteri DSM 17938 can inhibit numerous disease-causing gut micro-organisms and provide balance to the healthy gut bacteria (the microbiota).
L. reuteri DSM 17938 meets and exceeds all criteria
for the optimal probiotic

Beyond the ideal probiotic criteria
Human origin
Clinical efficacy
Human clinical trials on exact strain in product
Gastric acid stability
Bile acid stability
Adherence to intestinal mucosa
Temporary colonisation
Documented clinical safety
Production of antimicrobial compounds
Antagonism against pathogenic organisms
Shelf life and stability during processing
  • Breast milk origin
  • 137 clinical trials
  • 137 clinical trials
  • Human and experimental research
  • Human and experimental research
  • Human research
  • Human research
  • Multiple trials across the ages
  • Including the unique reuterin
  • Multiple pathogen antagonism
  • CFU count exceeds shelf life
Probiotics must meet certain criteria to be called probiotics but also to be beneficial in the human body.

Surviving passage through the stomach acid and the intestinal bile acid is crucial for a probiotic to have a beneficial effect in the small and large intestines.

Being able to attach to and temporarily colonise the intestinal wall is also highly beneficial but not crucial. Few probiotics have proven colonisation; however, L. reuteri has shown proven temporary colonisation in human subjects.

​​​​​​​ Antagonism against disease-causing organisms is another optimal criterion. Uniquely, L. reuteri DSM 17938 is a prolific producer of an antimicrobial substance called reuterin. No other species of bacteria produces reuterin. 
The probiotic with proven modes of action from clinical and experimental trials

A probiotic’s ability to communicate with its host will determine how efficient it is.

This interaction can be referred to as a probiotic’s mode of action.

Different probiotic strains communicate in different ways; therefore, it is very important to choose a strain that speaks the right language.
Watch 3 min video on multiple modes of action of the DSM 17938 probiotic strain
Strain specificity – using the right probiotic for the right situation
Human clinical and experimental studies have very clearly proven that two different strains of the same species do not behave the same.

Probiotics are strain specific, condition specific and dose specific.

Most other L. reuteri strains have never been tested in clinical trials, and even less often been proven efficient.

Strain specificity is crucial for the correct probiotic choice
The most efficient producer of the powerful antimicrobial substance – reuterin

Reuterin, a unique molecule, which has antimicrobial, antiviral and antifungal properties.
​​​​​​​L. reuteri is the only probiotic species that produces antimicrobial reuterin (3-hydroxypropionaldehyde).
Watch a short video about reuterin production
Although all L. reuteri produce reuterin, the DSM 17938 strain is the most efficient producer.
Antimicrobial effectiveness of L. reuteri DSM 17938
in clinical trials and experimental studies

L. reuteri DSM 17938 –
Sourced from humans and a proven transient coloniser
This species is the only probiotic studied throughout the whole human GI tract using biopsies.

It is robust, withstands the gut’s harsh environment and adheres easily to the intestinal wall.

It is the only probiotic in the world that has been shown in a published clinical trial to significantly colonise the stomach, duodenum and ileum of healthy humans in situ, temporarily.

L. reuteri has been isolated from human:

• Saliva
• Breast milk
• Stomach
• Small intestine
• Colon
• Faeces
• Vagina
For optimal gut health you need to cover three safeguards
So they are diverse (contain a wide range of bacteria), can limit disease causing organisms and produce substances that support the health and function of the gut.

By tightening the gut wall and improving growth of the intestinal cells, the intestines can function more effetctively, wash out pathogens more easily, and limit unwanted substances crossing the intestinal wall into the blood stream.

3. IMPROVED IMMUNE RESPONSE. With 80-85% of the body’s immune cells in the gut it is highly beneficial for a probiotic to have a direct impact on modulating gut immune health.

L. reuteri DSM 17938 covers all three GIT safeguards

Covering the three safeguards for GIT health
1. Strengthening of the microbiota

• Inhibition of pathogens
• Production of reuterin
• Production of lactic and acetic acids
• Production of exopolysaccharides (EPS)

2. Improvement of mucosa integrity

• Tightening the epithelial lining
• Improving epithelial growth

3. Improved immune response

• Production of IgA
• Activation of CD4+ T-helper cells

Lactobacillus reuteri DSM 17938 – the strain that speaks our language.
Grounded in evolution, driven by science.

For health advice consult with your health professional. 

For more information on this ground-breaking clinically researched strain please contact:

Health professionals assistance line: 1300 551 077 (AUS) | +64 9 845 1245 (NZ)